


AMENDMENTS TO THE CLAIMS

Claims 1-22 (canceled).

Claim 23 (currently amended): A method of inactivating antigen-specific T cells in an individual in need of such treatment, comprising the step of administering to said individual an effective amount of a compound of structure



[[II]]

wherein n_1 is 1-5;

X is O or NH;

Y is CH_2 , O[[,]] S, or NR;

~~wherein R is selected from the group consisting of hydrogen, a straight-chain aliphatic group, a branched-chain aliphatic group and an alicyclic group; and~~

~~R' is selected from the group consisting of~~ hydrogen, methyl ~~and or~~ ethyl;

or a pharmaceutically acceptable salt thereof.

Claim 24 (original): The method of claim 23, wherein said compound is 2-(4-morpholinyl)ethyl butanamide or a pharmaceutically acceptable salt thereof.

Claim 25 (currently amended): The method of claim 23, wherein said compound is 2-(4-morpholinyl)ethyl ~~butanoate~~ butyrate or a pharmaceutically acceptable salt thereof.

Claim 26 (currently amended): The method of claim 23, wherein inactivation of antigen-specific T cells is useful in the prophylaxis or therapeutic treatment of ~~an~~ autoimmune disease[[s]], a disorder[[s]] involving an autoimmune component or a neoplastic disease[[s]].

Claim 27 (currently amended): The method of claim 26, wherein said autoimmune disease[[s]] ~~are selected from the~~

~~group consisting of~~ is rheumatoid arthritis, systemic lupus erythematosus, diabetes, ~~and or~~ multiple sclerosis.

Claim 28 (currently amended): The method of claim 26, wherein said disorder[[s]] involving an autoimmune component ~~are selected from the group consisting of~~ is an allograft transplantation rejection ~~and or a~~ xenograft transplantation rejection.

Claim 29 (currently amended): The method of claim 26, wherein said neoplastic disease is ~~selected from the group consisting of~~ renal cancer, ovarian cancer, lung cancer, glioma ~~and or~~ leukemia.

Claims 30-40 (canceled).